Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
72.00    2.00 (2.86%)
Bid:
71.00
Ask:
73.00
Spread: 2.00 (2.817%)
Market Cap: £327.68m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Sch 1 - Readybuy PLC

21 Jul 2006 10:15

AIM21 July 2006 ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH AIM RULE 2 ALL APPLICANTS MUST COMPLETE THE FOLLOWING: COMPANY NAME:Readybuy plc COMPANY ADDRESS:Television House, 10-12 Mount Street, Manchester COMPANY POSTCODE:M2 5NT COUNTRY OF INCORPORATION:England and Wales COMPANY BUSINESS OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTMENT STRATEGY TO BE DISCLOSED INACCORDANCE WITH SCHEDULE 2, PARAGRAPH (J) OF THE AIM RULES:Since the Readybuy group's trading activities were terminated in July 2005, the directors of Readybuy have beenexploring the future options available to the Company. The Company's investing strategy is to acquire a companyinvolved in developing enabling technologies, particularly in the defence and bio-chemistry sectors. The Boardbelieves that the proposed acquisition of Avacta meets this investment strategy. Avacta was spun-out from the University of Leeds in January 2004 by its current management team as a biophysicscompany, with the aim of combining the disciplines of physics and biology to develop innovative technologies toaddress needs in the homeland security, pharmaceutical and clinical diagnostic markets. Avacta has two core activities: the development of detection technology platforms designed to meet the needs ofits target markets; and the provision of analytical services relating to the chemical and physical analysis ofmaterials to a range of companies, principally in the pharmaceutical, healthcare and personal care sectors. DETAILS OF SECURITIES TO BE ADMITTED (i.e. where known, number of shares, nominal value and issue price to whichit seeks admission and the number and type to be held as treasury shares):644,857,446 ordinary shares of 0.1p each on First Admission 24,469,898 ordinary shares of 0.1p each on Second AdmissionCAPITAL TO BE RAISED ON ADMISSION:£1,012,500 before expenses, by means of a placing of 45,000,000 ordinary shares of 0.1p each at 2.25p per share FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS:Directors: Daron Ross Lee (non-executive Chairman) Professor David Alastair Maclaughlin Smith (non-executive director and proposed Chief Executive followingAdmission) Proposed Directors: Dr. Gwynfor Owen Humphreys (proposed non-executive Chairman)Dr. Simon Webster (proposed Chief Scientific Officer)Dr. Kurt Justin Baldwin (proposed Chief Technology Officer)Timothy James Sykes (proposed Chief Financial Officer and proposed Company Secretary)Professor Anthony William Robards (proposed non-executive director)Alan John Aubrey (propose non-executive director) PERSON(S) INTERESTED IN 3% OR MORE OF THE ISSUER'S CAPITAL, EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITALBEFORE AND AFTER ADMISSION:Before: Robert Quested (29.76%)Christopher Potts (16.96%)Stephen James (16.09%)Robert Quested, Christopher Potts and Stephen James are also interested in warrants to subscribe for 18,500,000;10,500,000; and 10,000,000 Ordinary Shares respectively. On Admission: Robert Quested (8.93%)Christopher Potts (3.15%)Stephen James (2.99%) The members of the Existing Concert Party, as at the date of this document, together hold 83.71% of the issuedshare capital of the Company, and will, immediately following the Placing and Admission hold 19.84 % thereof.The members of the New Concert Party (being the vendors of Avacta), as at the date of this document, togetherhold 0.96% of the issued share capital of the Company, and will, immediately following the Placing and Admissionhold 74.88% thereof. NAMES AND ADDRESSES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:None ANTICIPATED ACCOUNTING REFERENCE DATE:30 April EXPECTED ADMISSION DATE:8 August 2006 (First Admission)9 August 2006 (Second Admission) NAME AND ADDRESS OF NOMINATED ADVISER:WH Ireland Limited11 St James's SquareManchesterM2 6WH NAME AND ADDRESS OF BROKER:WH Ireland Limited11 St James's SquareManchesterM2 6WH DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENTTHAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:Copies of the admission document containing full details about the applicant and the admission of its securitieswill be available free of charge to the public until at least one month after admission at the offices of:- WH Ireland Limited11 St James's SquareManchesterM2 6WH DATE OF NOTIFICATION:21 July 2006 NEW/ UPDATE (see note):New This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jun 20263:00 pmRNSBlock Listing - Application to AIM
1st Jun 20267:00 amRNSClinical data on AVA6000 in salivary gland cancers
29th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
29th May 20267:00 amRNSBoard Director Changes
19th May 20267:00 amRNSUnaudited Preliminary Full Year 2025 Results
13th May 20267:00 amRNSNotice of Preliminary Results and Presentation
13th May 20267:00 amRNSIssue of Equity and Total Voting Rights
6th May 20267:00 amRNSPre|CISION® payload release vs approved ADCs
28th Apr 20267:00 amRNSBlock Listing Six Monthly Return
21st Apr 20267:00 amRNSAvacta data AACR underline AVA6103 profile
14th Apr 202611:37 amRNS-RChristina Coughlin - In Vivo 2026 Rising Leader
9th Apr 20267:00 amRNSQ1 2026 Business Update
8th Apr 20267:00 amRNS-RAvacta Announces Science Day 2026
31st Mar 20267:00 amRNSFirst patient treated in Phase 1 trial of AVA6103
27th Mar 20267:00 amRNSResult of Oversubscribed Fundraise
26th Mar 20265:16 pmRNSProposed Fundraise to raise approximately £10m
26th Mar 20264:44 pmRNSIssue of Equity
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
24th Feb 20267:00 amRNSPreCISION payload delivery advantage over ADC
18th Feb 20267:00 amRNS-RAvacta to Participate in Conference March 2026
9th Feb 20267:00 amRNSAppointment of CSO
3rd Feb 20267:00 amRNSFaridoxorubicin Program Clinical Updates
21st Jan 20267:00 amRNSFDA Clearance of IND Application for AVA6103
20th Jan 20267:01 amRNSYear-end trading update
20th Jan 20267:00 amRNSAppointment of Nominated Adviser & TVR
18th Dec 20257:00 amRNS-RAvacta reports new AVA6103 pharmacology data
17th Dec 20257:00 amRNSFaridoxorubicin Phase 1b SGC data
8th Dec 20257:00 amRNSPreliminary Data in Faridoxorubicin Phase 1b Trial
3rd Nov 20258:24 amRNSCompletion of Placing and TVR
27th Oct 20255:39 pmRNSBlock Listing Six Monthly Return
27th Oct 20257:00 amRNSAvacta presents preclinical data at AACR-NCI-EORTC
23rd Oct 20255:00 pmRNS-RNotice of Investor Presentation
20th Oct 20257:01 amRNSEquity fundraise of £16 million
20th Oct 20257:00 amRNSAvacta Presents Phase 1a Data for Faridoxorubicin
13th Oct 20257:00 amRNSAvacta to present data at EORTC-NCI-AACR
30th Sep 20257:00 amRNSInterim Half Year Results 2025
15th Sep 20257:00 amRNSNotice of Interim Results
9th Sep 20257:00 amRNS-RShortlisted for AIM Awards Technology of the Year
1st Sep 20257:00 amRNSAvacta completes sale of Coris Bioconcept
29th Aug 20257:00 amRNSAmendments to Convertible Bond + equity fundraise
30th Jul 20257:00 amRNSAvacta to Present at ESMO Congress
28th Jul 20257:48 amRNSAgreement to Sell Coris Bioconcept SRL
21st Jul 20257:00 amRNSPayment of Convertible Bond Installment
17th Jul 20257:00 amRNSEquity fundraise of £3.25 million
2nd Jul 20255:00 pmRNSResult of AGM
2nd Jul 20257:00 amRNSQ2 2025 Business Update
1st Jul 20257:00 amRNSManagement Team Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.